EGRX · Eagle Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $64.65M | $66.31M | - | $65.90M | $74.14M | $115.87M | - | $39.85M | $48.12M | $41.25M |
| Cost of Revenue | $16.86M | $17.30M | - | $20.87M | $21.17M | $25.18M | - | $5.49M | $7.91M | $8.44M |
| Gross Profit | $47.79M | $49.01M | - | $45.03M | $52.97M | $90.70M | - | $34.37M | $40.22M | $32.81M |
| R&D | $9.83M | $9.27M | - | $9.33M | $11.44M | $6.11M | - | $23.29M | $9.91M | $14.29M |
| SG&A | $27.65M | $27.96M | - | $23.46M | $36.83M | $22.18M | - | $18.48M | $16.64M | $19.88M |
| Total Operating Expenses | $54.34M | $54.53M | - | $56.44M | $71.93M | $56.05M | - | $50.03M | $37.30M | $45.02M |
| D&A | $100.0K | $100.0K | - | $200.0K | $200.0K | $200.0K | - | $197.0K | $188.0K | $190.0K |
| Operating Income | $10.30M | $11.77M | - | $9.46M | $2.20M | $59.83M | - | ($10.18M) | $10.82M | ($3.77M) |
| Interest Expense | $1.45M | $1.52M | - | $1.15M | $552.0K | $366.0K | - | $396.0K | $422.0K | $422.0K |
| Income Tax | $4.13M | $4.48M | - | $3.47M | $3.58M | $13.60M | - | ($7.04M) | $1.94M | $1.76M |
| Net Income | $5.16M | $5.75M | - | ($7.13M) | ($9.45M) | $44.06M | - | ($5.62M) | $3.61M | ($421.0K) |
| EPS - Basic | $0.39 | $0.44 | - | ($0.54) | ($0.74) | $3.47 | - | ($0.43) | $0.28 | ($0.03) |
| EPS - Diluted | $0.39 | $0.44 | - | ($0.54) | ($0.74) | $3.41 | - | ($0.43) | $0.27 | ($0.03) |
Balance Sheet
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15.35M | $21.90M | $55.32M | $15.38M | $36.56M | $69.52M | $97.66M | $99.74M | $108.72M | $105.23M |
| Accounts Receivable | $115.14M | $114.95M | $72.44M | $96.93M | $85.92M | $130.86M | $41.15M | $45.34M | $52.66M | $44.87M |
| Inventory | $42.48M | $44.14M | $47.79M | $63.85M | $57.71M | $24.82M | $21.91M | $9.31M | $8.29M | $6.86M |
| Accounts Payable | $15.84M | $17.11M | $18.99M | $13.21M | $19.97M | $14.51M | $16.43M | $12.72M | $11.14M | $12.56M |
| Current Assets | $187.25M | $192.49M | $188.75M | $185.05M | $194.46M | $240.17M | $172.61M | $171.69M | $175.50M | $163.99M |
| Total Assets | $404.82M | $414.18M | $406.16M | $386.45M | $381.76M | $320.17M | $253.73M | $256.26M | $264.24M | $259.97M |
| Current Liabilities | $86.63M | $97.81M | $111.09M | $121.83M | $108.96M | $101.64M | $74.38M | $48.43M | $44.66M | $41.97M |
| Long-term Debt | $61.90M | $68.83M | $56.22M | $26.43M | $28.02M | $24.00M | $0 | $19.49M | $21.37M | $23.25M |
| Total Liabilities | $152.78M | $171.33M | $172.60M | $154.67M | $143.77M | $104.20M | $77.28M | $70.97M | $69.39M | $68.89M |
| Stockholders' Equity | $252.04M | $242.84M | $233.56M | $231.78M | $237.98M | $215.96M | $176.45M | $185.29M | $194.85M | $191.08M |
| Retained Earnings | $122.42M | $117.25M | $111.50M | $103.34M | $110.47M | $119.92M | $75.86M | $82.06M | $87.68M | $84.07M |
Cash Flow
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($33.51M) | - | - | - | ($16.61M) | - | - | - | $10.48M |
| Investing Cash Flow | - | ($12.56M) | - | - | - | ($168.0K) | - | - | - | ($5.38M) |
| Financing Cash Flow | - | $12.65M | - | - | - | ($11.36M) | - | - | - | ($3.02M) |
| CapEx | - | $58.0K | - | - | - | $168.0K | - | - | - | $384.0K |
| Free Cash Flow | - | ($33.57M) | - | - | - | ($16.78M) | - | - | - | $10.09M |
Ratios
| Metric | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 73.9% | 73.9% | - | 68.3% | 71.4% | 78.3% | - | 86.2% | 83.6% | 79.5% |
| Operating margin | 15.9% | 17.8% | - | 14.4% | 3.0% | 51.6% | - | -25.5% | 22.5% | -9.1% |
| EBITDA margin | 16.1% | 17.9% | - | 14.7% | 3.2% | 51.8% | - | -25.0% | 22.9% | -8.7% |
| Net margin | 8.0% | 8.7% | - | -10.8% | -12.7% | 38.0% | - | -14.1% | 7.5% | -1.0% |
| Free cash flow margin | - | -50.6% | - | - | - | -14.5% | - | - | - | 24.5% |
| FCF / Net income | - | -5.84 | - | - | - | -0.38 | - | - | - | -23.98 |
| R&D / Revenue | 15.2% | 14.0% | - | 14.2% | 15.4% | 5.3% | - | 58.4% | 20.6% | 34.6% |
| SG&A / Revenue | 42.8% | 42.2% | - | 35.6% | 49.7% | 19.1% | - | 46.4% | 34.6% | 48.2% |
| Effective tax rate | 44.5% | 43.8% | - | - | - | 23.6% | - | - | 34.9% | 131.4% |
| Return on assets | 1.3% | 1.4% | - | -1.8% | -2.5% | 13.8% | - | -2.2% | 1.4% | -0.2% |
| Return on equity | 2.0% | 2.4% | - | -3.1% | -4.0% | 20.4% | - | -3.0% | 1.9% | -0.2% |
| Return on invested capital | 1.8% | 2.1% | - | 2.9% | 0.7% | 19.1% | - | -3.9% | 3.3% | -0.9% |
| Liquidity | ||||||||||
| Current ratio | 2.16 | 1.97 | 1.70 | 1.52 | 1.78 | 2.36 | 2.32 | 3.55 | 3.93 | 3.91 |
| Quick ratio | 1.67 | 1.52 | 1.27 | 0.99 | 1.25 | 2.12 | 2.03 | 3.35 | 3.74 | 3.74 |
| Cash ratio | 0.18 | 0.22 | 0.50 | 0.13 | 0.34 | 0.68 | 1.31 | 2.06 | 2.43 | 2.51 |
| Leverage | ||||||||||
| Debt / Equity | 0.25 | 0.28 | 0.24 | 0.11 | 0.12 | 0.11 | 0.00 | 0.11 | 0.11 | 0.12 |
| Debt / Assets | 0.15 | 0.17 | 0.14 | 0.07 | 0.07 | 0.07 | 0.00 | 0.08 | 0.08 | 0.09 |
| Debt / EBITDA | 5.95 | 5.80 | - | 2.74 | 11.66 | 0.40 | - | - | 1.94 | - |
| Interest coverage | 7.1x | 7.8x | - | 8.2x | 4.0x | 163.5x | - | -25.7x | 25.6x | -8.9x |
| Equity multiplier | 1.61 | 1.71 | 1.74 | 1.67 | 1.60 | 1.48 | 1.44 | 1.38 | 1.36 | 1.36 |
| Liabilities / Assets | 0.38 | 0.41 | 0.42 | 0.40 | 0.38 | 0.33 | 0.30 | 0.28 | 0.26 | 0.26 |
| Efficiency | ||||||||||
| Asset turnover | 0.16 | 0.16 | - | 0.17 | 0.19 | 0.36 | - | 0.16 | 0.18 | 0.16 |
| Inventory turnover | 0.40 | 0.39 | - | 0.33 | 0.37 | 1.01 | - | 0.59 | 0.95 | 1.23 |
| Days sales outstanding | 650d | 633d | - | 537d | 423d | 412d | - | 415d | 399d | 397d |
| Days inventory outstanding | 920d | 931d | - | 1117d | 995d | 360d | - | 620d | 383d | 297d |
| Days payable outstanding | 343d | 361d | - | 231d | 344d | 210d | - | 846d | 514d | 543d |
| Cash conversion cycle | 1227d | 1203d | - | 1423d | 1074d | 562d | - | 189d | 268d | 151d |
| Valuation | ||||||||||
| P / E | 49.8x | - | - | - | - | - | - | - | - | - |
| P / B | 1.0x | - | - | - | - | - | - | - | - | - |
| P / S | 4.0x | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | 29.1x | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -12.8% | -42.8% | - | 65.4% | 54.1% | 180.9% | - | -20.2% | 14.8% | -10.4% |
| Revenue CAGR (3y) | 15.5% | 12.9% | - | 17.0% | 9.3% | 32.5% | - | -14.2% | -1.3% | -4.0% |
| Revenue CAGR (5y) | 5.2% | 7.3% | - | 0.9% | 8.1% | 8.6% | - | 1.0% | 3.3% | 6.9% |
| Gross profit growth (YoY) | -9.8% | -46.0% | - | 31.0% | 31.7% | 176.5% | - | -16.6% | 27.2% | -20.5% |
| Operating income growth (YoY) | 367.7% | -80.3% | - | - | -79.6% | - | - | - | 191.7% | - |
| Net income growth (YoY) | - | -86.9% | - | -26.8% | - | - | - | - | - | 85.3% |
| EPS growth (YoY) | - | -87.1% | - | -25.6% | - | - | - | - | - | 85.7% |
| EPS CAGR (3y) | - | - | - | - | - | 76.5% | - | - | 16.7% | - |
| EPS CAGR (5y) | 18.1% | 20.9% | - | - | - | 19.1% | - | - | -19.5% | - |
| FCF growth (YoY) | - | -100.1% | - | - | - | - | - | - | - | 275.8% |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | 34.4% |
| Book value growth (YoY) | 5.9% | 12.4% | 32.4% | 25.1% | 22.1% | 13.0% | -5.1% | 7.2% | 5.9% | 5.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$236.57M totalRoyalty$106.52M · 45.0%
Product$65.02M · 27.5%
Ryanodex$25.27M · 10.7%
Big Bagor Belrapzo$23.73M · 10.0%
Bendeka$11.17M · 4.7%
Other Product$4.86M · 2.1%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing EAGLE PHARMACEUTICALS against the 5 most active filers in the same SIC group.